BeBetter Med

BeBetter Med is a rapidly growing novel drug discovery and development company based in Guangzhou, China. Founded in 2012 by overseas returnees, the company is dedicated to creating advanced novel medicines for the treatment of cancer and other severe diseases. With a focus on clinical-stage drug discovery and development, BeBetter Med has positioned itself as a strong contender in the Health Care and Pharmaceutical industries. The company boasts a robust pipeline with eight innovative drug candidates, all with proprietary intellectual property rights. Notably, BEBT-908 has progressed to the pivotal phase II trial for the treatment of lymphoma, while BEBT-209 and BEBT-109 are in the phase Ib/II trial for breast cancer and lung cancer, respectively. This demonstrates BeBetter Med's commitment to tackling a varied spectrum of severe illnesses with its comprehensive pharmaceutical research capabilities extending from drug design and synthesis to clinical development. In November 2019, the company received a Venture Round investment from Lucky Source Funds, signifying external validation and support for its vision and capabilities. This investment underscores the confidence of industry stakeholders in BeBetter Med's potential to bring several new drugs to the market in the coming years. With a strong foundation and a promising portfolio, BeBetter Med presents an intriguing opportunity for investors seeking to participate in the advancement of cutting-edge treatments for critical medical conditions.